Gaithersburg, Md.-based Novavax’s commercial-scale manufacturing is expected to produce 100 million doses of the investigational vaccine that would become available for use in clinical trials or, should the FDA grant emergency use authorization (EUA) or approval, the government would be able to distribute the doses as part of a COVID-19 vaccine campaign, according to a news release.
Get the full story at our sister site, Pharmaceutical Processing World.